跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
RINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADA
Approved
STANDARD
RINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADA
Abbvie Deutschland Gmbh & Co. Kg
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Oct 11, 2022
Approval ID
8a5241841e9a8225
Company
Abbvie Deutschland Gmbh & Co. Kg
Type
Standard
Approval Details
Approval Id
8a5241841e9a8225
Drug Cima Aemps Name
RINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADA
Register Number
1191404010
Holder Company Name
Abbvie Deutschland Gmbh & Co. Kg
Marketing Company Name
Abbvie Spain, S.L.U.
Holder Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Authorization Date
2022-10-11
Dosage Form
COMPRIMIDO DE LIBERACIÓN PROLONGADA
Dose
45 MG
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Abbvie Deutschland Gmbh & Co. Kg
Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Company Information
Pharmaceutical Company Name
AbbVie Deutschland GmbH & Co. KG
Country Name
Germany
City Name
ludwigshafen am rhein,rheinland-pfalz,country_de
Address
Knollstr. 50
Website
http://www.abbvie.de
Active Ingredients
UPADACITINIB HEMIHIDRATO
46,1 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Oct 11, 2022
Approval ID
8a5241841e9a8225
Type
Standard
Back to CIMA-AEMPS Approvals
